Introducing a unique 12-hour treatment course for cystitis.

Complete in two doses
Now you can treat cystitis with unparalleled simplicity.
With the new Amoxil Twinpack you have a complete course for cystitis — in only 2 x 3g sachets. The two doses are taken 10 to 12 hours apart.
Proven to be just as effective as a conventional 10 day treatment course, Amoxil Twinpack provides rapid and complete symptomatic relief. With a promise of patient compliance that's simply unique.

Amoxil 3g x 2
Twin Pack
amoxicillin

Preparations
Indications Amoxil Twinpack (3g x 2) is intended for the treatment of simple, acute urinary tract infections such as cystitis in adults.
Dosage Adults: Two 3g doses, 10-12 hours apart. Presentation Carton containing 2 sachets. Each sachet provides 3g amoxicillin (as the citrate for reconstitution to approximately 30ml). Instruct it to be taken with meals or snacks. Includes full instructions for dosage and administration. Basic NHS cost per complete course £2.85. PL 0035/04.3
Contra-Indications Amoxil is a penicillin and should not be given to penicillin-hypersensitive patients.
Side-effects Side-effects, as with other penicillins, are usually of a minor and transitory nature. They include diarrhea, rash, itching, or occasionally, other reactions. Specific reactions include diarrhea, rash, and urticarial-type reactions. Hypersensitivity and/or erythematous type rash may also occur. Amoxil is administered to patients with penicillin allergy. If required, in other penicillin-type reactions use amoxicillin and amoxicillin-potent penicillin, such as disopyramide, and amoxicillin disopyramide.
A New Children's Classic

Talpen Syrup

talampicillin

Talpen syrup is one therapeutic agent which might claim to be a classic from the start. 
Talpen syrup offers the benefits of Talpen for the treatment of bacterial infections in children:
- Talpen offers ampicillin's rapid bactericidal action to resolve infection quickly and thus reduce pain and fever.
- Talpen is very well tolerated. Its excellent absorption means that the incidence of diarrhoea is very low.
- Talpen is acceptable to your patients.

A very pleasant fruit flavour coupled with a simple t.i.d. dosage ensure that Talpen syrup will be liked by children—and appreciated by their mothers as well.


Talpen Prescribing Information

Following oral administration Talpen is particularly well absorbed and rapidly hydrolysed to give high blood levels of ampicillin. Typical indications include: Upper Respiratory Tract Infections, Bronchitis, Otitis Media, Urinary Tract Infections. Presentations: Talpen syrup: Each 5 ml contains talampicillin napsylate (657 mg) equivalent to 250 mg talampicillin hydrochloride. Available in bottles of 100 ml. Talpen tablets: Each tablet contains 250 mg of the ampicillin ester, talampicillin hydrochloride. Usual Oral Dosage: Children 2-30 years: 5 ml syrup three times a day; under 2 years, the equivalent of 3.75 mg talampicillin hydrochloride per kg bodyweight three times a day. Adults: 1 tablet or 20 ml syrup three times a day. Contra-Indication: Penicillin hypersensitivity. Precaution: Talpen is not recommended for patients with severe renal or hepatic impairment. Side-effects: As with other penicillins. An erythematous rash may occasionally occur the incidence is particularly high in patients with infectious mononucleosis. The incidence of diarrhoea as a side-effect is significantly lower following the administration of Talpen than following oral ampicillin. Daily Cost: (Basic NHS). Talpen syrup: 5 ml t.i.d. 25p. Talpen tablets: one t.i.d. 25p (ex 100 pack). Prices correct at January 1979.

Further information is available on request to the Company. Talpen (talampicillin) is a product of British research from Beecham Research Laboratories, Brentford, England. A branch of Beecham Group Limited.
NEW PRODUCT from MSD research

Ophthalmic Solution

TIMOPTOL®

Timolol maleate, MSD

The most significant advance in the topical treatment of glaucoma since the introduction of pilocarpine

Merck Sharp & Dohme is pleased to introduce Ophthalmic Solution 'Timoptol' (timolol maleate, MSD), a beta-adrenergic blocking agent used topically to reduce intra-ocular pressure in patients with chronic open-angle glaucoma.

'Timoptol' has been shown in clinical studies to be generally effective in more patients than pilocarpine or adrenaline. It has the additional advantages of not affecting pupil size nor visual acuity due to increased accommodation and has very few adverse side effects. Also 'Timoptol' maintains a reduced intra-ocular pressure in most patients, with only a twice-daily dosage.

Merck Sharp & Dohme Limited, Hoddesdon, Hertfordshire, EN11 9BU

PRESCRIBING INFORMATION

Indication: Ophthalmic Solution TIMOPTOL should be used in patients with acute iritis, iridocyclitis, or irritable eye conditions to reduce intra-ocular pressure.

Dosage and administration: Recommended therapy is one drop 0.25% solution in the affected eye twice a day. If systemic reaction is noted, dosage may be increased to one drop 0.5% solution in the affected eye twice a day. If intra-ocular pressure is maintained at satisfactory levels, fewer patients can then be placed on once-a-day therapy. Because of naturally occurring intra-ocular pressure variations, patients should be instructed to report any increase in intra-ocular pressure during the day.

Clincial trials have shown the addition of TIMOPTOL to be useful in patients who respond incompletely to previous treatment. If necessary, the use of other anti-glaucoma agents can be continued concomitantly with TIMOPTOL. The maximum tolerated intra-ocular pressure is not significantly altered by the use of TIMOPTOL.

Contraindications: TIMOPTOL is contraindicated in patients who have shown sensitivity to the drug or to other beta-adrenergic blocking agents.

Warnings: TIMOPTOL contains timolol maleate, which is a beta-blocking agent. Use with caution in patients with known hypersensitivity to beta-blockers or in patients with bronchial asthma or other bronchospastic diseases. Close observation is advisable in patients with pre-existing cardiac disease, particularly if a heart rate of 50 beats per minute is achieved.

Side effects: Adverse reactions to TIMOPTOL are rare. Cases of mild skin rash, rash, pruritus, or urticaria have been reported. These reactions usually disappear when TIMOPTOL is discontinued. No other significant side effects have been reported.

Presentation: Ophthalmic Solution TIMOPTOL is supplied in a vial of 5 ml containing 0.05% timolol maleate. The vial should be stored at room temperature and protected from light.

The United Kingdom IMS basic cost is £4.15 for 5 ml of 0.25% Ophthalmic Solution TIMOPTOL.

The European Union IMS basic cost is £0.99 for 5 ml of 0.25% Ophthalmic Solution TIMOPTOL.

Product licence numbers: 0.25% Ophthalmic Solution 0023550104 0.5% Ophthalmic Solution 0023550106 Product registration numbers: 0.25% Ophthalmic Solution 35532 0.5% Ophthalmic Solution 35533 Additional information is available on request from the medical profession or from the company. 79-6556
A delicate skin problem but one that must be solved

When prescribing a topical steroid to treat a delicate area, a major consideration is to avoid the risk of untoward effects.

Eumovate fulfills the need for a topical steroid with a wide margin of safety, providing significant anti-inflammatory activity without a corresponding increase in the risk of side effects.

Clinical evidence has shown that the minimal effect on HPA function observed with Eumovate was in definite contrast to that seen with other preparations.


Prescribing information
Uses
Eumovate is suitable for treating the milder forms of eczema, seborrhoeic dermatitis and other steroid responsive skin conditions.

Dosage and administration
Apply up to four times a day until improvement occurs. When the frequency may be reduced.

Side effects
With topical corticosteroids local atrophic changes may possibly occur following prolonged and intensive treatment. Also prolonged use of large amounts or treatment of extensive areas may produce the features of hypercorticism. This is more likely to occur in infants and children, and with occlusion. In infants, the napkin may act as an occlusive dressing.

In the unlikely event of signs of hypersensitivity appearing, application should stop immediately.

Precautions
Long-term continuous therapy should be avoided, particularly in infants and children in whom adrenal suppression can occur even without occlusion. Appropriate chemotherapy should be used whenever infection of the skin is present. Any spread of infection requires withdrawal of topical corticosteroid therapy.

With all corticosteroids, prolonged application to the face is undesirable.

Topical steroids should not be used extensively in pregnancy, i.e., in large amounts or for prolonged periods.

Contraindications
Bacterial, fungal or viral diseases of the skin.

Basic NHS cost (exclusive of VAT)
Eumovate Cream or Ointment 25 gram tube £7.23 (also available in 100 gram tubes)
Product Licence number
cream 4/0233
ointment 4/0254

Glaxo
Leaders in topical steroid therapy
Glaxo Laboratories Ltd
Greenford, Middlesex UB6 8HE
Eumovate is a trade mark

Eumovate
(clobetasone butyrate)
An investment in safety and efficacy
IT'S FAST ACTING
IT'S RELIABLE
IT'S EFFECTIVE
IT'S PROVEN

IT'S SYNALAR
Fluocinolone acetonide
The economical range of topical steroids.

Full prescribing information is available on request.

Pharmaceuticals Division
Macclesfield
Cheshire SK10 4TF.
The third in a series of Hibernating animals: the Brown Bear (Ursus arctos arctos) hibernates from mid November

For safe, natural, undisturbed sleep...

REMNOS
Nitrazepam/DDSA

- Rapidly induces natural sleep
- Increases the duration of sleep and reduces the number of nocturnal awakenings
- No hangover or confusion on waking
- Minimum changes in REM pattern

- Small dependence risk
- High comparative safety in overdosage
- Well tolerated and producing no unwanted systemic effects
- Uniquely available in two strengths (5mg & 10mg)

Presentation circular blister 12mm tablets marked DDSA on converse with single break line on reverse, containing Nitrazepam BP white 5mg, yellow 10mg. (Uses an effective hypnotic agent recommended when a rapid onset of sleep is required.) REMnos increases total sleep time lasting 6-8 hours, with a reduced number of nocturnal awakenings. REMnos does not act by depression of brain structures, but promotes sleep with minimal changes in the rapid eye movement pattern (REM). Sleep disturbances due to organic conditions, tension, stress, anxiety and depression. The treatment of insomnia in the chronically ill requiring long or short term hypnatics. Pre-operative sleep. Dosage and administration: adults - the recommended dose is 5mg before retiring. This may be increased to 10mg. Hospital in patients may receive up to 20mg. Delirious and elderly patients - 2.5 to 5mg. Treatment should be commenced with the smaller 2.5mg dose in the elderly. REMnos is not recommended for administration to children. Contra-indications, warnings, etc: It is not advisable that REMnos be used in pregnancy and lactation. Patients receiving treatment with REMnos should be warned against the dangers of taking alcohol, barbiturates and other CNS depressants, and to exercise great care in handling mechanical equipment and driving motorized vehicles. Care should be taken in patients with respiratory depression. Side effects such as dizziness and drowsiness may occur, although hangover effect is minimal. Overdosage, evidenced by ataxia, slurred speech and drowsiness, gastric irritation and symptomatic treatment. Pharmacological precautions: protect from light and store in a well-closed container in a dry cool place.

Further information available on request from DDSA Pharmaceuticals, 310 Old Brompton Road London SW5 9JQ
"Good blood pressure control was obtained easily and the treatment regimen was simpler than that with previous therapy received by the patients. Few incremental changes in dosage were required and all but six (10%) patients were controlled by labetalol alone."

(Current Medical Research and Opinion, 1978, 5, 618)
simplifies the management of hypertension

for the doctor

- Trandate provides effective control of the hypertension
- Trandate is suitable for a wide range of patients
- Trandate obviates the need for multi-drug regimens or fixed combination products
- Trandate needs few incremental changes in dosage for control of most patients.

and for the patient

- The overall incidence of side effects is low
- Trandate avoids unwanted effects such as sedation and lack of energy
- The dosage regimen is simple – just one tablet two or three times a day
- Patients feel better on Trandate and the treatment does not restrict activity

“It is therefore particularly encouraging that 74% of patients in this study reported that they were much less tired, more energetic, more active physically and more mentally relaxed than when on their previous antihypertensive therapy.”

(Practitioner, 1979, 222, 131)
Medical Aid at Accidents
‘This book covers the basic knowledge required for most aspects of emergency care and rescue organisation by a series of short, relevant, and beautifully illustrated chapters... This is a significant contribution to the discipline of emergency care and can be recommended for use internationally.’ The Lancet

Rehabilitation Today
‘Every medical practitioner, every medical student (and every dean) should... have access to a copy of this book... Its use as a source of reference should become second nature.’ British Medical Journal

Dermatology
‘The first edition of this book was a landmark in medical publishing. The second edition contains 506 new colour illustrations, together with a comprehensive text. It will have immediate practical value to general practitioners, physicians, dermatologists, students and all others with an interest in this field.’

Neonatal Medicine
‘The text is factual, concise and easy to read. It correlates theory with clinical practice, and progresses smoothly from the assessment of the unborn child to care of the newborn, unborn or abnormal... This hardback book gives excellent value for money.’ Nursing Times

Oral Disease
‘Oral Disease would make a very valuable addition to the book collection of the dental student... The book will also serve as a valuable revision text for the general dental practitioner and the general medical practitioner, whose training in oral disease has usually been minimal.’ British Dental Students’ Association Newsletter.

Immunisation

Preventive Dentistry
Leon Silverstone, 1978, 74 figures, 176pp, hardback, ISBN 0 906141 06 0, price £5.95, post and packing free.

Interpreting the Electrocardiogram
James S. Fleming, 1979, 245 figures, 144pp, hardback, ISBN 0 906141 05 2, price £6.75 post and packing free.

UPDATE BOOKS
Order form on page 446
VENTOLIN ROTACAPS
(salbutamol sulphate BP inhalation cartridges for use with the Ventolin Rotahaler)

Improved control of asthma

VENTOLIN INHALER is widely accepted as primary therapy in the treatment of reversible airways obstruction in asthma and chronic bronchitis.

However, until the advent of VENTOLIN ROTACAPS a number of patients have been denied, for one reason or another, the benefits of inhaled Ventolin.

The Rotacaps/Rotahaler system was developed with these patients in mind. The dry powder contents of Ventolin Rotacaps are inhaled from the Ventolin Rotahaler which cuts the capsules into halves which rotate and release the drug when the patient inhales. This breath actuation is very sensitive and the drug is fully available even at the lowest inspiratory flow rates thus providing a more reliable drug delivery system for many patients although a larger unit dose relative to Ventolin Inhaler is necessary for the same therapeutic effect.

"This device (Ventolin Rotacaps and Rotahaler) should increase the value of the sympathomimetic drugs to the minority of asthma patients who cannot use conventional aerosols correctly."


SUITABLE CANDIDATES

- Poor co-ordinators – those patients who despite adequate instruction in the correct technique, cannot co-ordinate the action of breathing in with the actuation of a pressurised aerosol.

- Elderly and arthritic patients – who have difficulty in handling pressurised aerosols. For these patients the Rotahaler may be kept loaded ready for the next required dose.
BECOTIDE ROTACAPS
(beclomethasone dipropionate BP inhalation cartridges for use with the Becotide Rotahaler)

for a wider range of patients

BECOTIDE INHALER has revolutionised the treatment of chronic asthma where inflammatory changes within the lungs reduce the response to bronchodilators.

However, there are a number of patients who have failed to obtain maximum effectiveness from Becotide Inhaler or have been considered unsuitable for inhaled steroid therapy.

BECOTIDE ROTACAPS are now available as a dry powder breath-actuated alternative to Becotide Inhaler. Used in conjunction with the Becotide Rotahaler they extend the benefits of inhaled steroid therapy to a wider range of patients with chronic asthma.

As with Ventolin Rotacaps a larger unit dose of drug relative to Becotide Inhaler is necessary to obtain the same therapeutic effect. Two strengths of Rotacaps are again available combining flexibility of dosage with a convenient regimen facilitating patient compliance.

"It was concluded that this new way of administering the drug (beclomethasone dipropionate) was effective in chronic asthma, and should allow most patients who cannot use conventional pressurised aerosols efficiently to benefit from inhaled corticosteroid treatment."


FOR ROTACAPS INCLUDE:

- Young children – where breath-actuated dry powder drug delivery systems appear to be more reliable. Rotacaps may be pre-loaded into the Rotahaler by the parent.

- Patients currently receiving oral therapy – because of concern over possible irresponsible use of pressurised aerosols. Rotacaps are also more appropriate for routine prophylaxis for those patients who might misunderstand the role of inhalers.
VENTOLIN ROTACAPS 200mcg & 400mcg
PRESCRIBING INFORMATION

PRESENTATION AND BASIC NHS COST
Ventolin Inhaler is a metered-dose aerosol delivering 100mcg salbutamol BP per actuation. Each canister contains 200 inhalations. Basic NHS cost £1.95.
Ventolin Rotacaps 200mcg & 400mcg each contain a mixture of the stated amount of microfine salbutamol BP (as sulphate), and larger particle lactose in light blue/colourless or dark blue/colourless hard gelatine capsules, respectively. Containers of 100. Basic NHS cost £2.96 and £4.00, respectively.

INDICATIONS
Routine control of bronchoconstriction in bronchial asthma, bronchitis and emphysema, or as required to relieve attacks of acute bronchospasm. Doses may also be taken before exertion to prevent exercise-induced asthma or before exposure to a known unavoidable challenge.

DOSE AND ADMINISTRATION
As single doses for the relief of acute bronchospasm, for managing intermittent episodes of asthma and to prevent exercise-induced bronchospasm.

Using Ventolin Inhaler – Adults: one or two inhalations.

Using Ventolin Inhaler – Children: one inhalation increasing to two if necessary.

Using Ventolin Rotacaps – Adults: one Ventolin Rotacap 200mcg or 400mcg.

Using Ventolin Rotacaps – Children: one Ventolin Rotacap 200mcg.

For chronic maintenance or prophylactic therapy.

Using Ventolin Inhaler – Adults: one or two inhalations three or four times a day.

Using Ventolin Rotacaps – Adults: one Ventolin Rotacap 400mcg three or four times a day.

Using Ventolin Rotacaps – Children: one Ventolin Rotacap 200mcg three or four times a day.

Contraindications
Ventolin Preparations should not be used for the prevention of threatened abortion.

PRECAUTIONS
If a previously effective dose of inhaled Ventolin fails to give relief lasting at least 3 hours, the patient should be advised to seek medical advice. Ventolin should be administered cautiously to patients suffering from thyrotoxicosis. Unnecessary administration of drugs during the first trimester of pregnancy is undesirable.

SIDE EFFECTS
No important side effects have been reported following treatment with inhaled Ventolin.

PRODUCT LICENCE NUMBERS
Ventolin Inhaler 0045/0022; Ventolin Rotacaps 200mcg 0045/0116; Ventolin Rotacaps 400mcg 0045/0117.

BECOTIDE ROTACAPS 100mcg & 200mcg
PRESCRIBING INFORMATION

PRESENTATION AND BASIC NHS COST
Becotide Inhaler is a metered-dose aerosol delivering 50mcg beclomethasone dipropionate per actuation. Each canister contains 200 inhalations. Basic NHS cost £2.90.
Becotide Rotacaps 100mcg & 200mcg each contain a mixture of the stated amount of microfine beclomethasone dipropionate BP and larger particle lactose in buff or chocolate-brown/colourless hard gelatine capsules, respectively. Containers of 100. Basic NHS cost £4.41 and £5.88, respectively.
Becotide Rotahaler, for use in conjunction with Becotide Rotacaps. Basic NHS cost 65p.

INDICATIONS
Bronchial asthma especially in patients whose asthma is not adequately controlled by bronchodilators and patients with severe asthma who would otherwise be dependent on systemic corticosteroids or adreno-corticotropic hormone (ACTH) or its synthetic equivalent.

DOSE AND ADMINISTRATION
Using Becotide Inhaler – Adults: Two inhalations three or four times a day is the usual maintenance dose. In severe cases dosage may be started at twelve to sixteen inhalations per day and subsequently reduced when the patient begins to respond.

Children: One or two inhalations, two, three or four times a day according to the response.

Using Becotide Rotahaler – Adults: One 200mcg Becotide Rotacap three or four times a day is the usual maintenance dose.

Children: One 100mcg Becotide Rotacap, two, three or four times a day according to the response.

CONTRA-INDICATIONS
No specific contra-indications to inhaled Becotide are known but special care is necessary in patients with active or quiescent pulmonary tuberculosis.

PRECAUTIONS
The maximum daily intake of beclomethasone dipropionate should not exceed 1mg. Inadequate response after the first week of inhaled Becotide therapy suggests that excessive mucus is preventing penetration of inhaled drug to the target area. A short course of systemic steroid in relatively high dosage should be given and therapy with inhaled Becotide continued.

Unnecessary administration of drugs during the first trimester of pregnancy is undesirable. When transferring patients to Becotide from systemic steroid therapy the possibility of adrenocortical suppression should be considered and patients given a supply of oral steroids for use during periods of stress. Please refer to the detailed procedure described in the data sheets for Becotide Inhaler and Becotide Rotacaps.

SIDE EFFECTS
Occasional candidiasis of the mouth and throat (thrust) occurs in some patients, particularly those with high blood levels of Candida precipitins. Topical therapy with antifungal agents usually clears the condition without withdrawal of Becotide.

PRODUCT LICENCE NUMBERS
Becotide Inhaler 0045/0088; Becotide Rotacaps 100mcg 0045/0119; Becotide Rotacaps 200mcg 0045/0120.

PATIENT INSTRUCTION
It is important to ensure that patients receiving inhalation therapy are correctly instructed in the use of the device being prescribed. For this purpose demonstration units are available on request from Allen & Hanburys Ltd. The patient's acquired technique should be monitored by re-checking at suitable intervals. Generally speaking, patients unable to use pressurised aerosols efficiently can be satisfactorily treated using the alternative Rotacap/Rotahaler system which, for them, provides a greater degree of certainty and a better guarantee of effectiveness. Any initial problems with the manipulation of the Rotahaler are usually overcome as the patient becomes more familiar with its use.

In the case of young children and patients with arthritis of the hands it may be preferable for the device to be loaded by the parent or other person. When Ventolin Rotacaps are being used for the relief of acute bronchospasm it may be convenient to load a Rotacap into the device so that the dose is readily available. Ventolin and Becotide Rotahalers are supplied in plastic boxes for carrying in the pocket or handbag. The daily requirement of Rotacaps may be inserted into the spaces provided in the box to encourage compliance. A replacement Ventolin or Becotide Rotahaler should be prescribed at approximately six-month intervals.

Who are the candidates for Rotacaps in your practice?

Full prescribing information is available on request. Ventolin, Becotide, Rotacap, Rotahaler are trade marks of ALLEN & HANBURYS LTD., London E2 6LA.
Classified advertisements are welcomed and should be sent to: Mr Mike Fulton, Advertisement Director, The Journal of the Royal College of General Practitioners, Update Publications Ltd., 33/34 Alfred Place, London WC1E 7DP. Copy must be received by the first of the month preceding the month of issue to ensure inclusion. Every effort will be made to include advertisements received after this date but publication cannot be guaranteed and the advertisement may have to be held over to the following issue.

The British Postgraduate Medical Federation has now published its programme of courses for general practitioners for the period September to December 1979. These programmes will be distributed automatically to general practitioners in the National Health Service in the four Thames Regional Health Authorities through their local Family Practitioner Committees. Any other general practitioner wishing to receive a copy of this programme, should forward a stamped addressed foolscap envelope to:

The General Practitioner Department, British Postgraduate Medical Federation, Regional Postgraduate Medical Dean’s Office, 14 Ulster Place, London NW1 5HD.

No applications will be accepted by telephone.

KENSINGTON

Trainee vacancy starting 1 September 1979 in modern four-partner practice with large list. New premises, well organized, advanced record system, students taught, research project. Half-day release, half day off.

Apply in writing with curriculum vitae to:
Dr Tom Trevelyan, MRCP, 2 Pelham Street, London SW7 2NG.

NORTH DEVON COAST

Partnership vacancy 1 August 1979.


Full curriculum vitae to and further details from:
Mrs Avril Purse, Practice Manager, Braunton 812005.

GENERAL PRACTITIONER required

for a three-doctor clinic in Northern British Columbia, Canada.

Must meet requirements of a minimum of six weeks each in Medicine, Surgery, Paediatrics, Obstetrics and Gynaecology — postgraduate training.

Looking for a general practitioner interested in permanent position, initially to work as a locum with view to full partnership. Very good remuneration.

Send résumé to:
Lazelle Medical Centre, Dr R. Brooks, 4656 Lazelle Avenue, Terrace, British Columbia, Canada V8G 1S6.

THE RUDOLF FRIEDLAENDER MEMORIAL FUND

The Trustees of the Rudolf Friedlaender Memorial Fund are able to provide annual grants of up to £500 (a) to enable general practitioners to travel within the UK or abroad to study new medical treatments or clinical techniques; (b) to enable general practitioners to prepare for publication information concerning medical treatments acquired in the course of their practices, by paying for necessary secretarial or other services and expenses incidental to such publication.

Application forms are available from: The Trustees, The Rudolf Friedlaender Memorial Fund, 8 Regent Street, Eccles, Manchester M30 0AP.
Opinions expressed in The Journal of the Royal College of General Practitioners and the occasional papers should not be taken to represent the policy of the Royal College of General Practitioners unless this is specifically stated.

WEST OF SCOTLAND COMMITTEE FOR POSTGRADUATE MEDICAL EDUCATION COURSE OF STUDIES IN GENERAL PRACTICE

5 to 9 November 1979
Ruchill Hospital, Glasgow G21

A course of studies in general practice structured on small group work and restricted to 30. Subjects covered will include: practice management, problem solving, prescribing, patient/doctor relationship, training for general practice and assessing quality of care.

This course is suitable for established practitioners although Trainees and Assistants may apply. The subject matter and format of the course makes it especially relevant to principals wishing to apply for recognition as trainers under the Trainee Practitioner Scheme, as well as partners of recognized trainers.

Residential accommodation is available and the course is approved under Section 63.

Further details may be obtained from: the Dean of Postgraduate Medicine, The University of Glasgow, Glasgow G12 8QQ. Telephone 041-339 8855, ext. 7274.

INDEX TO ADVERTISERS

<table>
<thead>
<tr>
<th>Allen &amp; Hanburys</th>
<th>page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beconase</td>
<td>inside back cover</td>
</tr>
<tr>
<td>Trimulate</td>
<td>400/1</td>
</tr>
<tr>
<td>Beecham Research Laboratories</td>
<td>386</td>
</tr>
<tr>
<td>Bencard Ltd</td>
<td>inside front cover</td>
</tr>
<tr>
<td>DDSA</td>
<td>398</td>
</tr>
<tr>
<td>Remnos</td>
<td>398</td>
</tr>
<tr>
<td>Duncan Flockhart</td>
<td>412</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Glaxo Laboratories</th>
<th>page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eumovate</td>
<td>390</td>
</tr>
<tr>
<td>ICI Ltd</td>
<td>Synalar</td>
</tr>
<tr>
<td>397</td>
<td></td>
</tr>
<tr>
<td>Leo Laboratories</td>
<td>Fucidin Topical</td>
</tr>
<tr>
<td>388</td>
<td></td>
</tr>
<tr>
<td>Merck Sharp &amp; Dohme</td>
<td>Timoptol</td>
</tr>
<tr>
<td>388</td>
<td></td>
</tr>
<tr>
<td>Update Publications</td>
<td>Corporate</td>
</tr>
<tr>
<td>414</td>
<td></td>
</tr>
<tr>
<td>Order form</td>
<td>446</td>
</tr>
</tbody>
</table>

UPDATE BOOKS ORDER FORM

Update Books are available from major bookshops and also through the post direct from Update. Post and packing are free.

All orders within the UK should be paid for at sterling prices and the order and remittance sent to Book Sales Dept, Update Books Ltd, 33-34 Alfred Place, London WC1E 7DP.

All orders outside the UK should be paid for at dollar prices and sent to Update Publishing International Inc., 44 Engle Street, Englewood, New Jersey 07631, USA.

Enter in the box the number of copies you require.

- Medical Aid at Accidents (£7.65/$19.00)
- Rehabilitation Today (£6.20/$11.50)
- Dermatology (£8.25/$19.00)
- Neonatal Medicine (£6.20/$10.50)
- Oral Disease (£6.20/$11.50)
- Immunisation (£4.20/$9.50)
- Preventive Dentistry (£5.95/$12.50)
- Interpreting the Electrocardiogram (£6.75/$16.50)

Write your name and address very clearly in block capitals.

NAME ...................................................

ADDRESS ...................................................

.......................................................

POSTCODE ...............................................

UK orders

Either I enclose cheque/PO for £........ made payable to Update Books Ltd.

or Please debit my Access/Barclaycard account for £........

Access/Barclaycard No........................................

Signature ..................................................

Orders outside the UK

I enclose cheque for £........ made payable to Update Publishing International Inc.

Money back guarantee. If you are in any way dissatisfied with an Update book and return it in perfect condition within 14 days your money will be refunded in full.

440000
Five years of extensive clinical experience have shown that Beconase used routinely throughout the season provides:

- Effective control of the nasal symptoms of hay fever
- Freedom from antihistamine induced drowsiness or rebound congestion from decongestants
- Convenient topical therapy delivered from an easy-to-use actuator

Ideally Beconase should be started before exposure to the allergen but it may also be used to relieve established nasal symptoms.

**Beconase NASAL SPRAY**
(Becloethasone dipropionate BP)

first line therapy in hay fever
Somebody has prescribed 30,000,000 tubes of fucidin...

is it YOU?

In boils, dirty wounds, impetigo and most other soft tissue bacterial infections, Fucidin works.

Topical Fucidin is available as Fucidin Gel, Fucidin H Gel, Fucidin H Ointment, Fucidin Tulle and Caviject... and of course

fucidin* ointment

Sodium Fusidate B.P.
Full prescribing information available from

Leo Laboratories Limited,
Hayes Gate House, Hayes, Middx.

*Fucidin is a trade mark for sodium fusidate.


Product Licence No: 0043/5005 Basic NHS Price: 10g 95p